Nick Leschly, the renowned CEO known for his work in gene therapy, has returned with a new venture called Altido Bio. This startup aims to bring to market a promising CAR-T cell therapy developed at Massachusetts General Hospital (MGH) for glioblastoma, a deadly brain tumor with a very low survival rate. Altido Bio recently secured a $12.5 million seed funding round led by ARCH Venture and is now in the process of raising a $75 million Series A round.
The CAR-T therapy being developed by Altido Bio has shown early but promising results in clinical trials. The initial data from the treatment have sparked excitement within the medical community due to the grim prognosis associated with glioblastoma. In the trial, all three of the first patients treated with the CAR-T therapy experienced significant shrinkage of their tumors. While two of the patients unfortunately relapsed and passed away, one patient remains alive and thriving over 2.5 years after receiving the treatment.
The potential of Altido Bio’s CAR-T therapy to effectively treat glioblastoma is a beacon of hope for patients and healthcare professionals alike. The company’s innovative approach and Leschly’s track record in the field of gene therapy have positioned Altido Bio as a key player in the fight against this devastating disease.
As the company continues to progress with its research and development efforts, the medical community eagerly awaits further updates on the efficacy and safety of Altido Bio’s CAR-T therapy. With the support of investors and the dedication of its team, Altido Bio is poised to make a significant impact in the field of oncology and bring new hope to patients facing the challenges of glioblastoma.
